Our top pick for
Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Strongbridge Biopharma plc is a biotechnology business based in the US. Strongbridge Biopharma shares (SBBP) are listed on the NASDAQ and all prices are listed in US Dollars. Strongbridge Biopharma employs 72 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$2.00|
|52-week range||$1.85 - $3.19|
|50-day moving average||$2.14|
|200-day moving average||$2.48|
|Wall St. target price||$5.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.63|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2022-06-24)||N/A|
|1 month (2022-06-01)||N/A|
|3 months (2022-04-01)||N/A|
|6 months (2022-01-01)||N/A|
|1 year (2021-07-02)||-35.06%|
|2 years (2020-07-02)||-45.80%|
|3 years (2019-07-05)||3.18|
|5 years (2017-07-05)||7.2|
|Revenue TTM||$34.7 million|
|Gross profit TTM||$28.5 million|
|Return on assets TTM||-27.5%|
|Return on equity TTM||-87.06%|
|Market capitalisation||$135.7 million|
TTM: trailing 12 months
We're not expecting Strongbridge Biopharma to pay a dividend over the next 12 months.
Over the last 12 months, Strongbridge Biopharma's shares have ranged in value from as little as $1.85 up to $3.19. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Strongbridge Biopharma's is 1.5958. This would suggest that Strongbridge Biopharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
As of October 5, 2021, Strongbridge Biopharma plc was acquired by Xeris Pharmaceuticals, Inc. Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs in the United States. The company offers Keveyis, an oral carbonic anhydrase inhibitor to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in Phase III clinical trials for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that has completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania. .
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.